New oral treatment available in France

Novo Nordisk’s oral version of its flagship injectable treatment is now being sold in France, starting Monday, November 2, the company announced. This marks a significant development for patients who previously had to use injections.

Similar effects to injectable version

The oral medication is said to have effects comparable to the injectable version, offering a potentially more convenient option for patients. However, the company has noted that this new form is not covered by public health reimbursement programs.

No reimbursement for the pills

As a result, patients who wish to use the oral treatment will have to pay out-of-pocket for the medication. This could pose a financial challenge for some individuals, especially those relying on public healthcare coverage.

Company highlights convenience

Novo Nordisk emphasized the convenience of the oral form, which may improve patient adherence to treatment. The company continues to research and develop new delivery methods for its medications.